Telomir Pharmaceuticals TELO
NASDAQ TELO
$1.02 +0.01 (+0.99%)
At close: Oct 21, 2026 · 4:00 PM EDT

Telomir Pharmaceuticals (TELO) Short term Debt (2023 - 2026)

Updated

Telomir Pharmaceuticals (TELO) reported Short term Debt of $136,372 for Q2 2026.

Analysis

Telomir Pharmaceuticals (TELO) Short term Debt (2023 - 2026) Analysis & Trends

At the end of FY2023, Telomir Pharmaceuticals posted Short term Debt of $101,000.

  • The Q2 2026 figure ranks as the lowest quarterly Short term Debt since Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Telomir Pharmaceuticals 62.66 Mn 42.09 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 136,372.00
Dec 31, 2023 101,000.00
API Access

Telomir Pharmaceuticals Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=TELO&period=max&api_key=YOUR_API_KEY